CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 70 enrolled
Drug / intervention
Botulinum Toxin A (Allergan, Inc, Irvine CA) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01760577
NCT01760577N/ACompleted
CompareCT.gov

Comparing Effects of Intraarticular Botulinum Toxin A Versus Hyaluronate Plus Rehabilitation Exercise in Patients With Unilateral Ankle Osteoarthritis

Kaohsiung Veterans General Hospital.·interventional·Posted Jan 4, 2013·Updated Jan 4, 2013

In Brief

A clinical study evaluating Botulinum Toxin A (Allergan, Inc, Irvine CA) and Hyalgan (Hyalgan, Fidia , Italy) for Ankle Osteoarthritis. Completed, enrolled 70 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the effects of intraarticular Botulinum Toxin A versus intraarticular hyaluronate plus rehabilitation exercise in patients with ankle osteoarthritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkle Osteoarthritis
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 4, 2013
Enrollment StartMay 1, 2010
Primary CompletionMay 1, 2012
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.5 years ago

Interventions

Botulinum Toxin A (Allergan, Inc, Irvine CA)drug

patients received intraarticular injections by the same experienced physician using aseptic procedures.

Hyalgan (Hyalgan, Fidia , Italy)drug

The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.